Imperagen
PrivateLast Round
Seed
May 21, 2026
Total Funding Raised
$13.05M
Momentum Score
25 /100
Company Overview
Imperagen is a biotechnology company that provides a digital enzyme evolution platform to accelerate enzyme engineering for the pharmaceutical and chemical industries.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, ML Platforms, Clean Manufacturing
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Imperagen Comps
Public and private peers based on sector, stage, and business model.
Imperagen Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | May 21, 2026 | ||||
| Seed | May 21, 2024 |
Key People
Founding team and executive leadership
Imperagen Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| IQ Capital | Seed |
| Northern Gritstone | Seed |
| PXN Group | Seed |
| PXN Ventures | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 21, 2026
$5M round led by PXN Group
- Jan 21, 2026
Grew 20% QoQ from 15 to 18 employees.
Imperagen Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Imperagen's valuation, stock price, and market status.
